Compare Cytokinetics Inc (CYTK) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs VICI Properties Inc — how do they compare? Cytokinetics Inc trades at $82.35 (market cap $11.12B), while VICI Properties Inc trades at $26.56 (market cap $28.94B). The key difference: VICI Properties Inc is far larger — about 2.6× Cytokinetics Inc's market cap, and VICI Properties Inc pays a 6.85% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | VICI | |
|---|---|---|
Market Cap | $11.12B | $28.94B |
Sector | Technology | Real Estate |
52-Week High | $87.26 | $33.93 |
52-Week Low | $33.23 | $25.94 |
Enterprise Value | $11.59B | $46.16B |
Dividend Yield | — | 6.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
VICI Properties trades at $26.40, up 1.5% on the day, with a bearish technical signal from moving averages but neutral oscillators. The REIT shows strong fundamentals with a P/E of 9, net income margin of 76.83%, and consistent cash flow generation. Recent news highlights its 6.8% dividend yield and investment-grade balance sheet, though concerns linger over tenant concentration with Caesars and MGM accounting for 70% of rent.
The outlook remains positive with a consensus price target of $30.75 implying 16.5% upside, supported by 20 buy ratings. Risks include Las Vegas market exposure and potential lease uncertainties from tenant buyouts, but the stock's discounted valuation and secure dividend profile offer a compelling case for income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
